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ABSTRACT 
The concept of therapeutic equivalence is becoming increasingly important in today’s cost – conscious environment. Though an effective 
therapy already exists, but clinically equivalent therapy also becoming important. An improved toxicity profile better effects on symptoms and 
ease of administration may be important considerations. In these positive controls substantial effect is required to define equivalence. The goal 
is to prove that the new treatment is not inferior to standard, since providing that two treatments are equal is not possible. The superiority 
trials demonstrate the better efficacy of the treatment against the concurrent placebo control.  Innovative drugs become available for the 
treatment of number of diseases. These, new products may offer some specific advantages over the standard drugs. The Placebo controlled 
trials are invariably unethical, when known effective therapy is available for the condition being studies. The active controlled trials are used 
extensively in the development of new pharmaceuticals. The equivalence limit is defined by a lower equivalence or upper equivalence limit . 
These, principles are proposed for setting such limits, depending on the objective of the study placebo conditions and methods based on 
statistical properties. 
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INTRODUCTION  
In pharmaceutical industries, for the development of 
therapeutic entities. Phase II and III of clinical trials are 
conducted for proving the effectiveness and safety of the 
drug. The goal of the trials is to obtain better efficacy of 
treatment against concurrent placebo control trial. For the 
treatment of number of diseases the remodelled or 
innovative drugs are used. A new therapeutic modalities are 
developed to compete with the standard products on the 
market. Therapeutic modalities may have some specific 
advantages over the standard drug. It has better safety 
profile improvement on the quality of life, an easy 
administration route, short duration of treatment and 
mainly the reduction of cost. Hence the new drug contains 
more benefits. But it is proving that its effectiveness is more 
than that of the standard drug. The sponsors should require 
the evidence that the test product is efficient than the 
standard. More efficacy and with some specific added values 
with safety profile provided to the new treatment is called 
Therapeutic equivalence. Hence these studies of therapeutic 
equivalence are called Non inferiority trials. Therapeutic 
equivalence only requires obtaining the efficacy of new 
treatment than the standard so it is referred as one sided 
equivalence. The patent of an innovative product expires, 
other companies may manufacture generic copies under 
drug price competition and patient term restoration act 
passed in 1984, Through the Abbreviated New drug 
Application (ANDA). The generic copies must be equivalent 
to the rearranged product based on pharmacokinetic pk 
such as area under plasma concentration time curve, area 
under curve (AUC) or peak concentration (cmax) obtained 
from bioequivalence studies. The average bioavailability of 
generic product is neither too high nor too low as compared 
to that of reference product. Hence, bioequivalence has 
importance in two sided equivalence. It has average 
bioequivalence, population bioequivalence and individual 
bioequivalence that are described in equivalence trials. 
ONE SIDED EQUIVALENCE AND NON INFERIORITY 
TRIALS 
The average efficacy of test and standard value of the drug 
would be µT and µS. large value gives a better efficacy. For 
an advanced trial, investigators are interested in detecting 
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whether a difference in efficacy exists between the test and 
standard drugs. Hence this   question can be given by 
following formulation of   Hypothesis. 
                     Ho: µT=µS versus Ha: µT≠µS               - 1 
Equation -1 is in the form of two sided hypothesis. All other 
argued that the advanced trial should be formulated as one 
sided. 
                            µa: µT > µS               - 2 
After the null hypothesis test there is no difference in both 
the equations. It can be proven at significant level. The null 
hypothesis µT - µS is not rejected the concentration of trial 
should never be proven in or trial. The difference may result 
from a poorly conducted trial that provides variable data 
and a large experimental error. Another side well designed 
and carefully executed trials generate reliable data to 
provide estimates of treatment effects with high accuracy 
and precision. The paradox is that the form of hypothesis in 
equation 1 is wrong hypothesis for obtaining of one sided 
equivalence in a non inferiority trial.  
The correct hypothesis will be one sided hypothesis to test 
whether test drug is more effect as standard drug. 
                          Ho: µT - µS ≤ L versus Ha: µT - µS >L          - 3 
L= maximum allowable limit of no clinical significance. 
This trial objective is that the test drug is more effective than 
the standard drug. It follows the equation -3 for the 
continuous end points from a two group parallel design 
which is compared to test drug of nT patient to the n S 
standard drug. YT –YS are the observed means of test and 
standard drug, S² is poored variance. 
           T = (ÝT – ÝS - / L) / S ^ 1/nt + 1/ ns > Z (α)                  - 4 
Z (α) is the α th upper quantile of the standard normal 
distribution equivalence is not only a testing procedure but 
also an estimation problem. The use of confidence interval 
for evaluation of both types of equivalence for one sided - (1 
– α) 100 % confidence limit is larger than lower equivalence 
limit. 
     (ÝT – ÝS) – Z (α) (S^ 1/ nt + 1/ ns)                           -5 
The confidence interval approach is more than the testing 
hypothesis procedure. It provides magnitude and range of 
average difference between two treatments.  For a two 
group parallel design with equal allocation. The same size 
per group required to give (1 – β). Hypothesis 3 can be 
estimated by following for 
                n = 2 [¬² / (∞ + L ²)] [Z (α) + Z (β)] ²                - 6 
Where ∞ = µT -µS > L is assumed as true difference in 
average effect between test and standard drugs. ¬² is 
common variable. Z (β) is the upper quantile of the standard 
normal distribution. From equation 6 Th sample size is a 
decreasing function of true unknown difference µT -µS when 
∞ = 0 formula 6 reduce to. 
                 n = 2 [¬ / L²] [Z (α) + Z (β)] ² 
For the evaluation of one sided equivalence based on binary 
end points from a two group parallel trial. The 
corresponding hypothesis are given  
                    Ho:  PT – PS ≤ L vs. Ha: PT – PS  > L          - 7 
Where PT and PS are the response rates of test and standard 
treatment equation – 7 is rejected and the test drug is more 
effective than the standard drug. 
                    Z = (PT – PS – L) / SE> Z (α)                           - 8 
Where SE ² = [pr (1 – pr) / nT] + [PS (1- PS/ ns)].The 
corresponding lower (1 – α) 100 % confidence limit and 
sample size estimation formula. 
                                (PT – PS) – Z (α) SE   and  
                             n = {SE² / [(PT – PS) + L] ²} {Z (α) + Z (β)} ². 
This is the assessment of equivalence between 2 survival 
functions. 
ACTIVE CONTROL EQUIVALENCE TRIALS  
The non inferiority trials demonstrated that the efficacy of 
test drug is more than the standard drug they are also 
referred as Active control equivalence trials. The critical 
criterion is the effectiveness of the standard drug. The test 
and standard drug are therapeutic equivalent that they can 
be either efficacious or inefficacious. A series of 6 trials were 
conducted to find out the effectiveness of new drug.  Ex: 
Imipramine. 
(HAM – D) from baseline between test drug and imipramine 
both drug produce a clinically meaningful mean reduction in 
HAM  - D. HAM- D is not rejected at 5% of significance level. 
The power to detect a 30 % difference is quite low.HAM – D 
and imipramine is compared with the placebo. Both the test 
drugs and imipramine are ineffective as compared to the 
placebo. If a concurrent placebo control were not there in 6 
trials, the test drug would have been stated the effect based 
on conjecture that the test drug and imipramine have similar 
efficacy. This example explains about the concurrent placebo 
control in active control equivalence trials unless the active 
standard has been proven efficacious inadequate well 
controlled studies. ACET has 3 treatments, a test drug active 
standard and placebo concurrent control. In addition to 
evaluate of therapeutic equivalence between test and 
standard. Hence the following hypothesis is formulated to 
evaluate these 2 major objectives. 
                       Ho: µT - µS≤ L or µT- µP ≤ O or µS - µP ≤ O. Vs.  
                       Ha: µT - µS > L and µT - µP > O and µS - µP > O 
Where µp is average efficacy of placebo. There are two more 
one sided hypothesis for evaluation of effectiveness in test 
and standard drugs as compared to placebo. 
                        Ho T: µT - µP ≤ O Vs µT - µP > O    and   
                        Ho S: µS - µP ≤ O Vs µS - µP > O 
Parameter space of null hypothesis in equation 9 is union of 
spaces of 3 null hypotheses in equation 3 and 10. Parameter 
space of alternative hypothesis is the intersection of spaces. 
Hence, all 3 one sided null hypothesis are rejected at 
significant level by intersection union principle. The null 
hypothesis in equation 9 is rejected at α significance level 
and it is concluded that both test and reference drugs are 
superior to placebo and are equivalent. This procedure is 
called as 3 one sided test procedures. This procedure can 
control consumes risk under the nominal level of 
significance. 
EQUIVALENCE LIMIT 
For some bioequivalence testing and some therapeutic areas 
the equivalence limits are usually expressed in terms of 
standard response. Equivalence limit are unknown 
parameters. For one sided therapeutic equivalence the lower 
limit L is determined by previous experience about 
estimated relative efficacy along with placebo and by 
maximum allowance below which clinicians consider to be 
therapeutic acceptable. It is not good to have an equivalence 
limit for evaluation of more efficacy as large as or even 
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larger than the treatment difference between the standard 
drug and the placebo. Ex: 3.2 limits are selected in treatment 
of perennial allergic rhinitis. It is selected for evaluation of  
therapeutic equivalence between a test and standard drug 
because  3.2 represents 25% of the sample range for the  
total symptom scores 3.2 limit not suitable for individual 
symptom scores 3.2 is for that total symptom scores 0.5 is 
for individual scores.  
Another example is continuous infusion versus double bolus 
administration of alteplase (COBALT). For fibrinolytic 
therapy of suspected acute myocardial infection, the 30 day 
mortality rate is about 12 % for placebo group and 8% for 
tissue plasminogen activator. Hence the treatment effect of 
tissue plasminogen activator against placebo is 4%. Cobalt 
investigators employed an equivalence limit of 0.4%. This 
limit is 1 / 10 of estimated relative treatment effect against 
placebo. This explains about the upper limit of deaths 
allowed for the double bolus alteplase to be considered. 
Therapeutic equivalence to accelerated infusion is 4 more 
deaths per 1000 patients. This number is few than 5.0 per 
1000 patients between alteplase and streptokinase. 
Therapeutic equivalence accelerated in a non inferiority trial 
should always be selected as a quantity smaller than the 
difference between standard drug and placebo that a 
superior trial is designed to detect. The ultimate and real 
goal of any inferiority trial is to prove that efficacy of the test 
treatment is better than that of placebo. 
RECENT DEVELOPMENT 
In the framework of hypothesis testing and regulatory 
considerations, kothmann et al have addressed the design 
and analysis of non inferiority trial based on survival for 
oncology trials. The European committee for medical 
products for human use (CHMP) issued a guideline for 
selection of non inferiority margin. Non inferiority testing 
has been applied to evaluation of accuracy of diagnostic 
devices. 
CONCLUSION          
For a non inferiority trial , the objectives of evaluation for 
equivalence between the test and the standard drugs and for 
superiority of both drugs over placebo should be clearly 
stated in the protocol. In addition, the equivalence limit 
should also be prespecified in the protocol with clinical and 
statistical justification. As indicated in (CH) an adequate 
active control is non inferiority trial should be a widely used 
standard. Therapeutic equivalence should have more 
efficiency and standard safety profile of drug. In general the 
intention to treat (HT) analysis will provide an estimate for 
treatment effect of a smaller magnitude than the per 
protocol (PP) analysis. Hence, the IIT analysis is not 
necessarily more likely to conclude therapeutic equivalence. 
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